Primary Outcome Measures The analysis of the primary efficacy endpoint will be conducted in all eligible patients, based on the disease control rate (DCR) at 12 weeks according to mRECIST 1.1 for mesothelioma, which was defined as the proportion of patients with compete response (CR), partial response (PR) or stable[…]
Pleural Mesothelioma
The Diagnostic Accuracy and Clinical Value of FAPI PET in Pleural Mesothelioma (FAPI-PM)
Primary Outcome Measures The diagnostic performance (sensitivity, specificity, positive predicative value, negative predicative value, and overall diagnostic accuracy – all parameters in %). in of FAPI PET compared to routine imaging modalities, including FDG PET/CT, in suspected PM lesions. Secondary Outcome Measures Calculate the proportion of patients where the location[…]
MARS 2 Trial for Mesothelioma
Malignant pleural mesothelioma is a deadly cancer mainly caused by asbestos exposure. It is a hard-to-treat cancer due to its aggressiveness. The cancer affects the pleura, which is the membrane that covers the lungs. A trial known as MARS 2 tried to find out if extended pleurectomy and decortication could[…]
The Diagnostic Accuracy and Clinical Value of FAPI PET in Pleural Mesothelioma (FAPI-PM)
Primary Outcome Measures Calculate the proportion of patients where the location of the intended pleural biopsy is altered due to FAPI PET/CT replacing FDG PET/CT. Secondary Outcome Measures Compare the cancer stage (IASCL 9th edition TNM-classification) as determined by FAPI PET/CT compared to conventional imaging (including FDG PET/CT) at primary[…]
Immune Checkpoint Inhibitors for the Treatment of Mesothelioma
Mesothelioma is a rare, aggressive cancer mainly caused by asbestos exposure. One treatment that is giving hope to patients and caregivers is the use of immune checkpoint inhibitors. A new study from Australia has raised questions about the effectiveness and safety of this novel treatment. In order to best care[…]
CAR-T Cell Therapy for Mesothelioma
Mesothelioma is a rare, yet aggressive cancer mainly caused by asbestos exposure. There are very limited options for treatment. This is especially true for elderly patients. Conventional therapies might not be the best option due to the person’s age and other health problems. Chimeric antigen receptor (CAR) T cell therapy[…]
New Preclinical and Clinical Approaches to Mesothelioma
This study protocol involves the coordination between UO1 (IRCCS San Raffaele Hospital) and UO2 (Istituto Nazionale Tumori di Napoli – IRCCS G. Pascale) to explore the role of HMGB1 and CXCR4 in cancer treatment and metastasis. UO1 focuses on the role of HMGB1 in inflammation, mesothelioma progression, and tissue repair, as well as developing, in future, possible HMGB1 inhibitors for cancer therapy. UO2 specializes in CXCR4’s role in cancer, developing CXCR4 antagonists, and tracking CXCR4-dependent metastasis. The hypothesis is that targeting HMGB1 and CXCR4 pathways will inhibit tumor progression and metastasis, enhancing anti-tumor immunity and improving therapeutic outcomes in cancer.
Using Precision Cut Tumor Slices to Advance Mesothelioma Treatment
Malignant pleural mesothelioma is a cancer mainly caused by asbestos exposure that is very deadly. Research continues to be done on the cancer, giving hope to patients and their families. One tool in the fight against mesothelioma is ex-vivo models using precision cut tumor slices. A new article looks at[…]
Pleurectomy and Decortication Vs Just Chemotherapy for Mesothelioma
Malignant pleural mesothelioma is a rare and deadly cancer mainly caused by asbestos exposure. It is hard to surgically remove and is very aggressive, which makes it hard to treat. A trial known as the MARS 2 trial investigated to see if pleurectomy and decortication could improve the quality of[…]
Surgery is Beneficial for Mesothelioma Patients
Pleural mesothelioma is a cancer mainly caused by asbestos exposure. It is a cancer of the pleura, which is a lining of the lungs. The outlook for the disease is poor, with a typical survival time after diagnosis being 9 to 20 months. The overall five-year survival rate is five[…]
